Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
Name:
36650166.pdf
Size:
410.9Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Coombes, R. C.Badman, P. D.
Lozano-Kuehne, J. P.
Liu, X.
Macpherson, I. R.
Zubairi, I.
Baird, R. D.
Rosenfeld, N.
Garcia-Corbacho, J.
Cresti, N.
Plummer, R.
Armstrong, Anne C
Allerton, R.
Landers, D.
Nicholas, H.
McLellan, L.
Lim, A.
Mouliere, F.
Pardo, O. E.
Ferguson, V.
Seckl, M. J.
Affiliation
Department of Surgery and Cancer, Imperial College London, London, UK.Issue Date
2023
Metadata
Show full item recordCitation
Coombes RC, Badman PD, Lozano-Kuehne JP, Liu X, Macpherson IR, Zubairi I, et al. Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nature communications. 2023 Jan 17;14(1):260. PubMed PMID: 36650166. Pubmed Central PMCID: PMC9845345. Epub 2023/01/18. eng.Journal
Nature CommunicationsDOI
10.1038/s41467-023-35969-4PubMed ID
36650166Additional Links
https://dx.doi.org/10.1038/s41467-023-35969-4Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41467-023-35969-4
Scopus Count
Collections
Related articles
- AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.
- Authors: Aytatli A, Barlak N, Sanli F, Caglar HO, Gundogdu B, Tatar A, Ittmann M, Karatas OF
- Issue date: 2022 Feb
- FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice.
- Authors: Zhao Q, Parris AB, Howard EW, Zhao M, Ma Z, Guo Z, Xing Y, Yang X
- Issue date: 2017 Sep 12
- AZD4547 and calcitriol synergistically inhibited BT-474 cell proliferation while modified stemness and tumorsphere formation.
- Authors: Morales-Guadarrama G, Méndez-Pérez EA, García-Quiroz J, Avila E, Larrea F, Díaz L
- Issue date: 2022 Oct
- SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
- Authors: Aggarwal C, Redman MW, Lara PN Jr, Borghaei H, Hoffman P, Bradley JD, Newman AJ 3rd, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR
- Issue date: 2019 Oct
- AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
- Authors: Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN, Klinowska T
- Issue date: 2012 Apr 15